Servier announces a strategic worldwide licensing agreement for Black Diamond Therapeutics’ BDTX-4933 for solid tumors for an upfront payment of $70 million and up to $710 million in milestone payments.
Servier announces a strategic worldwide licensing agreement for Black Diamond Therapeutics’ BDTX-4933 for solid tumors for an upfront payment of $70 million and up to $710 million in milestone payments.
Copyright © Louis Velazquez. All Rights Reserved.